Dow AgroSciences | GenomeWeb

Dow AgroSciences

The technology is based on engineered zinc finger DNA-binding proteins, which bind to specific functional domains to create transcription factors capable of activating or repressing target genes.

The funding will support support two alliances between industry and academia that are applying genomic technologies to agriculture and healthcare.

The deal expands the companies' ongoing collaboration, which began in mid-2015, to include additional natural product targets in crop protection and traits.

Critical Path will license Dow AgroScience's Plextein technology for multiplex detection of plant proteins using mass spectroscopy and provide it as a service.

The company will work with the Institute of Crop Sciences of the Chinese Academy of Agricultural Sciences to develop the technology into a rice genome-editing platform.

In the study, company researchers explored treating corn rootworms with RNAi molecules that would interfere with the viability of their offspring.

The companies will work together to discover and develop natural products for crop protection.

NEW YORK (GenomeWeb) – In Nature Genetics, an international team led by investigators at the National Institute on Aging presented findings from a meta-analysis of Parkinson's disease genome-wi

NEW YORK (GenomeWeb) – Dow AgroSciences said today that Sigma-Aldrich will manufacture and supply zinc finger nuclease reagents for use with Dow AgroSciences' Exzact Precision Technology, a genome modification platform for plants.

While chemical proteomics has traditionally focused on pharmaceutical work, several recent collaborations suggest that the field is establishing a foothold within agricultural research, as well.

Pages

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.